Home
NewsNewsLG Chem’s App for Infertility and Pregnancy Preparation, Bloom, brings together fertility education, treatment explanations, emotional support, and preparation tools in one digital platform. Designed as a companion rather than a clinical service, the app addresses growing information gaps faced by individuals and couples navigating infertility and pregnancy preparation.
Infertility has become a significant concern in modern society, with delayed marriages, environmental factors, and lifestyle changes contributing to increased fertility challenges. As more individuals and couples seek support during pregnancy preparation, digital healthcare tools are emerging to bridge the information gap. One such platform is the Bloom app for infertility and pregnancy preparation, developed by LG Chem in collaboration with leading reproductive medicine organizations in Korea.
Unveiled in September 2025, Bloom isn’t just another health app. It is a digital healthcare platform designed to give people scientifically grounded guidance on fertility, infertility, and preparing the body and mind for pregnancy. LG Chem positioned Bloom as a companion for women aiming to conceive, couples facing difficulties conceiving, and individuals looking toward future fertility preservation. The app’s name carries metaphorical weight: a blend of new life, hope, and the full bloom of possibility.
Infertility is no longer a fringe issue. Demographic shifts, like later marriages and changing lifestyles, mean that increasing numbers of couples confront conception challenges. But beyond statistics, the emotional landscape can be heavy: confusion, countless online searches, and uncertainty about what steps to take next. LG Chem’s internal research suggested that while information exists, it’s scattered, technical, and often hard for laypeople to parse. Bloom aims to centralize that information and make it usable.
The Bloom app for infertility and pregnancy preparation includes several informational and support components:
A few months after its release, Bloom gained industry validation. In December 2025, the app won the grand prize in the medical service category at the Smart App Awards, one of Korea’s respected tech recognitions, judged by a 4,000-member panel assessing design, user interface, content quality, and technological innovation.
The award citation emphasized Bloom’s scientific approach to supporting both infertility and pregnancy preparation, acknowledging that these are not purely personal concerns but broader public health issues. Such recognition suggests that the app’s design aligns with real-world needs, not just corporate ambition.
While the Bloom app for infertility and pregnancy preparation serves as a comprehensive information resource, it functions as a supplementary tool to professional medical consultation. The app provides educational content and practical guidance but does not replace individualized medical advice from fertility specialists or reproductive endocrinologists.
The Bloom app for infertility and pregnancy preparation represents an effort to consolidate infertility-related information, emotional support resources, and practical preparation materials into a single digital platform. By providing expert-verified content and community features, the Bloom app for infertility and pregnancy preparation addresses some of the informational and emotional needs individuals and couples face during pregnancy preparation and infertility treatment journeys.
apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.
Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.
TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.
CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.
Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.
UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.
Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.
